# Phase I Study of Oral DFP-11207 in Solid Tumors

Source: https://onco.cc/trials/nct02171221/  
OnCo record `nct02171221` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of DFP-11207 run by Delta-Fly Pharma, Inc., completed.

## Summary

Phase I Study of Oral DFP-11207 in Solid Tumors is a phase 1 interventional study registered as NCT02171221 by Delta-Fly Pharma, Inc., with 23 participants enrolled, started 2014-06. Conditions recorded: Solid Tumors and Cancer. Interventions recorded: Oral DFP-11207.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02171221
- Phase: 1
- Setting: A Phase I Study of Once-Daily Oral DFP-11207 in Patients With Solid Tumors
- Sponsor: Delta-Fly Pharma, Inc.
- Enrolled: 23

## Sources

- ClinicalTrials.gov NCT02171221: https://clinicaltrials.gov/study/NCT02171221

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [DFP-11207](https://onco.cc/drugs/dfp-11207/)
- companies: [Delta-Fly Pharma](https://onco.cc/companies/delta-fly-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct02171221.json